石药集团(01093)：KN026联合HB1801新辅助治疗HER2阳性乳腺癌的III期临床研究结果于2026年ASCO年会以LBA口头报告形式呈列

智通财经06-01 08:13

智通财经APP讯，石药集团(01093)发布公告，公司附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司(康宁杰瑞)合作开发的HER2双特异性抗体安尼妥单抗(商品名：恩尼妥^®)(KN026)联合集团自主研发的注射用多西他赛(白蛋白结合型)(HB1801)新辅助治疗HER2阳性乳腺癌的III期临床研究(研究编号：KN026–004/Neo-Healer)的结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要(LBA)口头报告形式呈列。

Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。主要研究终点为盲法独立评估委员会(BIRC)评估的总体病理完全缓解率(tpCR)，研究共入组521例患者，按1：1比例随机分配至试验组(安尼妥单抗联合HB1801±卡铂)或对照组(曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂)，均接受6个周期治疗。患者入组时根据三项因素进行分层：(i)临床分期;(ii)激素受体状态;(iii)是否计划使用卡铂。

研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640813439?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-01 08:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640813439","market":"hk","top_or_hot":-1,"title":"石药集团(01093)：KN026联合HB1801新辅助治疗HER2阳性乳腺癌的III期临床研究结果于2026年ASCO年会以LBA口头报告形式呈列","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01093\">石药集团</a>(01093)发布公告，公司附属公司上海津曼特生物科技有限公司与江苏<a href=\"https://laohu8.com/S/09966\">康宁杰瑞</a>生物制药有限公司(<a href=\"https://laohu8.com/S/GLW\">康宁</a>杰瑞)合作开发的HER2双特异性抗体安尼妥单抗(商品名：恩尼妥<sup>®</sup>)(KN026)<a href=\"https://laohu8.com/S/00373\">联合集团</a>自主研发的注射用多西他赛(白蛋白结合型)(HB1801)新辅助治疗HER2阳性乳腺癌的III期临床研究(研究编号：KN026–004/Neo-Healer)的结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要(LBA)口头报告形式呈列。</p><p>Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。主要研究终点为盲法独立评估委员会(BIRC)评估的总体病理完全缓解率(tpCR)，研究共入组521例患者，按1：1比例随机分配至试验组(安尼妥单抗联合HB1801±卡铂)或对照组(曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂)，均接受6个周期治疗。患者入组时根据三项因素进行分层：(i)临床分期;(ii)激素受体状态;(iii)是否计划使用卡铂。</p><p>研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：KN026联合HB1801新辅助治疗HER2阳性乳腺癌的III期临床研究结果于2026年ASCO年会以LBA口头报告形式呈列</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：KN026联合HB1801新辅助治疗HER2阳性乳腺癌的III期临床研究结果于2026年ASCO年会以LBA口头报告形式呈列\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01093\">石药集团</a>(01093)发布公告，公司附属公司上海津曼特生物科技有限公司与江苏<a href=\"https://laohu8.com/S/09966\">康宁杰瑞</a>生物制药有限公司(<a href=\"https://laohu8.com/S/GLW\">康宁</a>杰瑞)合作开发的HER2双特异性抗体安尼妥单抗(商品名：恩尼妥<sup>®</sup>)(KN026)<a href=\"https://laohu8.com/S/00373\">联合集团</a>自主研发的注射用多西他赛(白蛋白结合型)(HB1801)新辅助治疗HER2阳性乳腺癌的III期临床研究(研究编号：KN026–004/Neo-Healer)的结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要(LBA)口头报告形式呈列。</p><p>Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。主要研究终点为盲法独立评估委员会(BIRC)评估的总体病理完全缓解率(tpCR)，研究共入组521例患者，按1：1比例随机分配至试验组(安尼妥单抗联合HB1801±卡铂)或对照组(曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂)，均接受6个周期治疗。患者入组时根据三项因素进行分层：(i)临床分期;(ii)激素受体状态;(iii)是否计划使用卡铂。</p><p>研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1448240.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0008368742.USD","symbol_name":"首域中国增长基金I Acc","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1448240.html","article_id":"2640813439","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640813439","pubTimestamp":1780272820,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1515":"抗疫概念","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","III":"信息服务","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01093":"石药集团","BK4134":"信息科技咨询与其它服务","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1191":"制药","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC"},"translate_title":"CSPC (01093): Phase III clinical study results of KN026 combined with HB1801 neoadjuvant therapy for HER2-positive breast cancer were presented as an LBA oral presentation at the 2026 ASCO Annual Meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"III":1.5},"content_text":"智通财经APP讯，石药集团(01093)发布公告，公司附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司(康宁杰瑞)合作开发的HER2双特异性抗体安尼妥单抗(商品名：恩尼妥®)(KN026)联合集团自主研发的注射用多西他赛(白蛋白结合型)(HB1801)新辅助治疗HER2阳性乳腺癌的III期临床研究(研究编号：KN026–004/Neo-Healer)的结果，已于2026年美国临床肿瘤学会(ASCO)年会上以最新突破性摘要(LBA)口头报告形式呈列。Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。主要研究终点为盲法独立评估委员会(BIRC)评估的总体病理完全缓解率(tpCR)，研究共入组521例患者，按1：1比例随机分配至试验组(安尼妥单抗联合HB1801±卡铂)或对照组(曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂)，均接受6个周期治疗。患者入组时根据三项因素进行分层：(i)临床分期;(ii)激素受体状态;(iii)是否计划使用卡铂。研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640813439","isCrawlerRequest":true}